English
Back
Download
Log in to access Online Inquiry
Back to the Top

Genting strikes gold in TauRx

Genting strikes gold in TauRx
After years of researches and studies , finally TauRx released the full results and presentation of Phase 3 clinical studies of the flagship medicine named HMTM .
$GENTING (3182.MY)$ is having a 20% stake in TauRx , in which it is currently not making profits as the principal product HMTM is still under development and yet to be commercialized.
With the data released from the clinical trials , it is likely that TauRx’s HMTM will get the approvals from authority of key market such as UK and US.
This is considered as “extra bonus” to Genting’s asset value , other than the current businesses. Maybank Investment Bank assigned a target price of RM 9.40 , if the product HMTM is approved and commercialized in the future
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
76
1
16
+0
2
Translate
Report
294K Views
Comment
Sign in to post a comment